365 related articles for article (PubMed ID: 12480560)
41. Durability of rifaximin response in hepatic encephalopathy.
Neff GW; Jones M; Broda T; Jonas M; Ravi R; Novick D; Kaiser TE; Kemmer N
J Clin Gastroenterol; 2012 Feb; 46(2):168-71. PubMed ID: 22011586
[TBL] [Abstract][Full Text] [Related]
42. The cost-effectiveness and budget impact of competing therapies in hepatic encephalopathy - a decision analysis.
Huang E; Esrailian E; Spiegel BM
Aliment Pharmacol Ther; 2007 Oct; 26(8):1147-61. PubMed ID: 17894657
[TBL] [Abstract][Full Text] [Related]
43. Lactitol versus lactulose in the treatment of chronic hepatic encephalopathy. A double-blind, randomised, cross-over study.
Morgan MY; Hawley KE; Stambuk D
J Hepatol; 1987 Apr; 4(2):236-44. PubMed ID: 3295020
[TBL] [Abstract][Full Text] [Related]
44. Rifaximin vs. conventional oral therapy for hepatic encephalopathy: a meta-analysis.
Eltawil KM; Laryea M; Peltekian K; Molinari M
World J Gastroenterol; 2012 Feb; 18(8):767-77. PubMed ID: 22371636
[TBL] [Abstract][Full Text] [Related]
45. Pharmacological prophylaxis of hepatic encephalopathy after transjugular intrahepatic portosystemic shunt: a randomized controlled study.
Riggio O; Masini A; Efrati C; Nicolao F; Angeloni S; Salvatori FM; Bezzi M; Attili AF; Merli M
J Hepatol; 2005 May; 42(5):674-9. PubMed ID: 15826716
[TBL] [Abstract][Full Text] [Related]
46. Lactitol in the treatment of chronic hepatic encephalopathy--a randomized cross-over comparison with lactulose.
Riggio O; Balducci G; Ariosto F; Merli M; Tremiterra S; Ziparo V; Capocaccia L
Hepatogastroenterology; 1990 Oct; 37(5):524-7. PubMed ID: 2253931
[TBL] [Abstract][Full Text] [Related]
47. Rifaximin ameliorates hepatic encephalopathy and endotoxemia without affecting the gut microbiome diversity.
Kaji K; Takaya H; Saikawa S; Furukawa M; Sato S; Kawaratani H; Kitade M; Moriya K; Namisaki T; Akahane T; Mitoro A; Yoshiji H
World J Gastroenterol; 2017 Dec; 23(47):8355-8366. PubMed ID: 29307995
[TBL] [Abstract][Full Text] [Related]
48. Comparison of once a day rifaximin to twice a day dosage in the prevention of recurrence of hepatic encephalopathy in patients with chronic liver disease.
Khokhar N; Qureshi MO; Ahmad S; Ahmad A; Khan HH; Shafqat F; Salih M
J Gastroenterol Hepatol; 2015 Sep; 30(9):1420-2. PubMed ID: 25867912
[TBL] [Abstract][Full Text] [Related]
49. [Rifaximin for hepatic encephalopathy in children. Case report].
Malla I; Torres Cerino V; Villa A; Cheang Y; Giacove G; Pedreira A; Silva M
Arch Argent Pediatr; 2011 Dec; 109(6):e113-5. PubMed ID: 22231877
[TBL] [Abstract][Full Text] [Related]
50. Rifaximin improves psychometric performance and health-related quality of life in patients with minimal hepatic encephalopathy (the RIME Trial).
Sidhu SS; Goyal O; Mishra BP; Sood A; Chhina RS; Soni RK
Am J Gastroenterol; 2011 Feb; 106(2):307-16. PubMed ID: 21157444
[TBL] [Abstract][Full Text] [Related]
51. Rifaximin treatment is associated with reduced risk of cirrhotic complications and prolonged overall survival in patients experiencing hepatic encephalopathy.
Kang SH; Lee YB; Lee JH; Nam JY; Chang Y; Cho H; Yoo JJ; Cho YY; Cho EJ; Yu SJ; Kim MY; Kim YJ; Baik SK; Yoon JH
Aliment Pharmacol Ther; 2017 Nov; 46(9):845-855. PubMed ID: 28836723
[TBL] [Abstract][Full Text] [Related]
52. Management of hepatic encephalopathy: focus on antibiotic therapy.
Festi D; Vestito A; Mazzella G; Roda E; Colecchia A
Digestion; 2006; 73 Suppl 1():94-101. PubMed ID: 16498257
[TBL] [Abstract][Full Text] [Related]
53. [Ameliorating effect of lactitol on experimental hepatic encephalopathy in Eck fistula dogs].
Watanabe M; Ozaki T; Mushiroi T; Ukai Y; Ueda F; Kimura K; Katoh M; Matsumoto A; Kotani E; Itoh S
Nihon Yakurigaku Zasshi; 1995 May; 105(5):403-13. PubMed ID: 7628788
[TBL] [Abstract][Full Text] [Related]
54. Randomized-controlled trial of rifaximin versus norfloxacin for secondary prophylaxis of spontaneous bacterial peritonitis.
Elfert A; Abo Ali L; Soliman S; Ibrahim S; Abd-Elsalam S
Eur J Gastroenterol Hepatol; 2016 Dec; 28(12):1450-1454. PubMed ID: 27512927
[TBL] [Abstract][Full Text] [Related]
55. Rifaximin may have a dramatic effect on hepatic encephalopathy.
Lamb C; Reddy AV
Clin Med (Lond); 2012 Oct; 12(5):489-90. PubMed ID: 23101155
[TBL] [Abstract][Full Text] [Related]
56. Efficacy and safety of rifaximin in Japanese patients with hepatic encephalopathy: A phase II/III, multicenter, randomized, evaluator-blinded, active-controlled trial and a phase III, multicenter, open trial.
Suzuki K; Endo R; Takikawa Y; Moriyasu F; Aoyagi Y; Moriwaki H; Terai S; Sakaida I; Sakai Y; Nishiguchi S; Ishikawa T; Takagi H; Naganuma A; Genda T; Ichida T; Takaguchi K; Miyazawa K; Okita K
Hepatol Res; 2018 May; 48(6):411-423. PubMed ID: 29235218
[TBL] [Abstract][Full Text] [Related]
57. Combination therapy for the treatment and prevention of hepatic encephalopathy.
Mohammad RA; Regal RE; Alaniz C
Ann Pharmacother; 2012 Nov; 46(11):1559-63. PubMed ID: 23092866
[TBL] [Abstract][Full Text] [Related]
58. Rifaximin versus nonabsorbable disaccharides in the management of hepatic encephalopathy: a meta-analysis.
Jiang Q; Jiang XH; Zheng MH; Jiang LM; Chen YP; Wang L
Eur J Gastroenterol Hepatol; 2008 Nov; 20(11):1064-70. PubMed ID: 19047837
[TBL] [Abstract][Full Text] [Related]
59. Therapeutic efficacy of L-ornithine-L-aspartate infusions in patients with cirrhosis and hepatic encephalopathy: results of a placebo-controlled, double-blind study.
Kircheis G; Nilius R; Held C; Berndt H; Buchner M; Görtelmeyer R; Hendricks R; Krüger B; Kuklinski B; Meister H; Otto HJ; Rink C; Rösch W; Stauch S
Hepatology; 1997 Jun; 25(6):1351-60. PubMed ID: 9185752
[TBL] [Abstract][Full Text] [Related]
60. Rifaximin for the treatment of hepatic encephalopathy.
Mantry PS; Munsaf S
Transplant Proc; 2010 Dec; 42(10):4543-7. PubMed ID: 21168733
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]